TW202402753A - 高純度化合物之製造方法及純化方法 - Google Patents

高純度化合物之製造方法及純化方法 Download PDF

Info

Publication number
TW202402753A
TW202402753A TW112111992A TW112111992A TW202402753A TW 202402753 A TW202402753 A TW 202402753A TW 112111992 A TW112111992 A TW 112111992A TW 112111992 A TW112111992 A TW 112111992A TW 202402753 A TW202402753 A TW 202402753A
Authority
TW
Taiwan
Prior art keywords
dihydro
pyrido
salt
benzodiazepine
diethylamino
Prior art date
Application number
TW112111992A
Other languages
English (en)
Chinese (zh)
Inventor
大野敦嗣
本田崇宏
Original Assignee
日商參天製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商參天製藥股份有限公司 filed Critical 日商參天製藥股份有限公司
Publication of TW202402753A publication Critical patent/TW202402753A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW112111992A 2022-03-30 2023-03-29 高純度化合物之製造方法及純化方法 TW202402753A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-056754 2022-03-30
JP2022056754 2022-03-30

Publications (1)

Publication Number Publication Date
TW202402753A true TW202402753A (zh) 2024-01-16

Family

ID=88202044

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112111992A TW202402753A (zh) 2022-03-30 2023-03-29 高純度化合物之製造方法及純化方法

Country Status (7)

Country Link
US (1) US20250214992A1 (https=)
EP (1) EP4506347A4 (https=)
JP (1) JPWO2023190663A1 (https=)
KR (1) KR20240168375A (https=)
CN (1) CN118946564A (https=)
TW (1) TW202402753A (https=)
WO (1) WO2023190663A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3409237A1 (de) 1984-03-14 1985-09-19 Dr. Karl Thomae Gmbh, 7950 Biberach Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3626095A1 (de) * 1986-07-31 1988-02-11 Thomae Gmbh Dr K Neue substituierte pyrido(2,3-b)(1,4)benzodiazepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
JPH09318772A (ja) 1996-05-28 1997-12-12 Rhythm Watch Co Ltd 装飾装置
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
CN114302726A (zh) 2020-08-04 2022-04-08 参天制药株式会社 用于治疗近视、预防近视及/或抑制近视发展的药剂
JP7253813B2 (ja) 2020-08-07 2023-04-07 株式会社ユニバーサルエンターテインメント 遊技機
WO2022080397A1 (ja) * 2020-10-14 2022-04-21 参天製薬株式会社 安定な医薬組成物
EP4501329A4 (en) * 2022-03-30 2026-03-25 Santen Pharmaceutical Co Ltd METHOD FOR STERILIZING AND PACKAGING A PHARMACEUTICAL PREPARATION

Also Published As

Publication number Publication date
EP4506347A4 (en) 2026-03-25
WO2023190663A1 (ja) 2023-10-05
US20250214992A1 (en) 2025-07-03
KR20240168375A (ko) 2024-11-29
CN118946564A (zh) 2024-11-12
JPWO2023190663A1 (https=) 2023-10-05
EP4506347A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
US10723700B2 (en) Salts of an LSD1 inhibitor
RU2726631C1 (ru) Гетероциклические спиросоединения в качестве ингибиторов magl
CA3050625C (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
JP2024540080A (ja) Ｉｒａｋ４分解剤およびその合成
UA121775C2 (uk) 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
CN107400134A (zh) 嘌呤衍生物的结晶形式
US20180044317A1 (en) Benzimidazole derivatives as bromodomain inhibitors
CN103635465A (zh) 制备手性化合物的方法
EA028038B1 (ru) Способ для промышленного производства 1-[(2-бромфенил)сульфонил]-5-метокси-3-[(4-метил-1-пиперазинил)метил]-1h-индол димезилат моногидрата
US20240083914A1 (en) Crystalline Polymorphs of a Muscarinic Acetylcholine Receptor Agonist
US20240279171A1 (en) Methods for preparing crystalline forms of amisulpride
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
US20180002310A1 (en) Crystalline forms of efinaconazole
CN117377658A (zh) 喹啉衍生物化合物的制备方法
TW202402753A (zh) 高純度化合物之製造方法及純化方法
JP2023536911A (ja) Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態
JP7152122B2 (ja) エダラボン塩
US20120059034A1 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
CN107652269A (zh) 甲磺酸氟马替尼中间体纯化方法
TW202540105A (zh) 1-((3S,4R)-3-((2-((1-乙基-1H-吡唑-4-基)胺基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)-4-氟哌啶-1-基)丙-2-烯-1-酮之酒石酸鹽、其結晶形式及其製備方法
JP2007514734A (ja) ２−｛４−’３−（４−クロロ−２−フルオロフェニル）−４−ピリミジン−４−イル−１ｈ−ピラゾール−５−イル！ピペリジン−１−イル｝−２−オキソエタノールの結晶形
HK40009601B (en) Crystalline polymorphs of a muscarinic acetylcholine receptor agonist
NZ792812A (en) Crystalline polymorphs of a muscarinic acetylcholine receptor agonist